Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05430828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Study acronym: AT-TARGET-IT
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 2000 to 5000
    • Primary completion date changed from estimate of Mar 7, 2024 to Jan 30, 2022
    • Study completion date: Mar 31, 2024 to Mar 31, 2030
    • Secondary endpoints: details revised at 1 of 1 entry
    v4
  2. Enrollment target: 798 to 2000v3 Show 5 more changesShow less
    • Primary completion date: Jan 27, 2022 to Mar 7, 2024
    • Trial status: Completed to Recruiting
    • Study sites: 9 to 27
    • Study completion date: Feb 1, 2022 to Mar 31, 2024
    • Eligibility criteria revised
  3. Eligibility criteria shortened, about 50 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
Trial Details
NCT Number NCT05430828
Lead Sponsor Federico II University
Conditions
(from sponsor)		 Hypercholesterolemia
Related terms Hypercholesterolemia
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov